期刊文献+

非诺贝特在难治性痛风治疗中的疗效及安全性观察 被引量:8

下载PDF
导出
摘要 目的探讨非诺贝特对难治性痛风患者的血尿酸、血脂及肌酐等指标的影响。方法 26例处于稳定期的难治性痛风患者,加用非诺贝特胶囊200mgqd,分别在基线、治疗后6周、12周,监测血尿酸(UA)、甘油三酯(TG)、总胆固醇(TC)、肌酐(SCR)及肝功能等指标。结果非诺贝特治疗6周后患者UA下降约17%,57.7%患者达到理想水平(<360mmol/L);12周后UA下降约26.1%,92.3%患者达到理想UA水平。UA、TG、TC及碱性磷酸酶,在应用非诺贝特治疗6周、12周后均有下降,3个时间点差异有统计学意义(均<0.01);SCR在非诺贝特治疗后略有上升,但差异无统计学意义(>0.05)。在非诺贝特治疗期间没有痛风性关节炎急性发作,12周后复查肾脏B超未见新发肾结石。结论非诺贝特可帮助难治性痛风患者降低UA水平,达到理想水平,促进尿酸结晶的溶解,降低血脂,减少心血管疾病的发生,安全性良好。
作者 刘伟丽 丁健
出处 《现代实用医学》 2013年第8期862-863,共2页 Modern Practical Medicine
  • 相关文献

参考文献7

  • 1刘湘源,郑晓娟.尿酸持续达标是难治性痛风治疗的关键[J].北京大学学报(医学版),2012,44(2):168-170. 被引量:47
  • 2Perez-Ruiz ETreating to target:an strat- egy to cure gout[J]. Rheumatolgy (Ox- ford),2009,48(suppl 2):9-12.
  • 3Terkeltaub R. Update on gout: new thera peutic strategies and options [J]. Nat Rev Rheumatol,2010,6(1):30-38.
  • 4Robert Terkeltaub. Novel therapies for treatment of gout and hyperuricemia [J]. Arthritis Research & Therapy,2009,11 (4): 236-247.
  • 5Ka T, Inokuchi T, Tsutsumi Z, et al. Ef- fects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases[J].Intemational Journal of Clinical Pharmacology and Therapeutics,2006,44(1):22-26.
  • 6Feher MD, Hepburn AL, Hogarth MB, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyper- uricaemia and gout[J].Rheumatology, 2003, 42(2):321-325.
  • 7Hepburn. AL, Hogarth. MB, Ball SG, et al. Fenofibrate lowers serum urate in pati- ents treated with allopurinol[J]. J Rheu- matology, 2001,28(suppl 63): 13-15.

二级参考文献15

  • 1Terkeltaub R.Update on gout:new therapeutic strategies and options[J].Nat Rev Rheumatol,2010,6(1):30-38.
  • 2Becker MA,Schumacher HR Jr,Wortmann RL,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout[J].N EnglJ Med,2005,353(23):2450-2461.
  • 3Perez-Ruiz F,Calabozo M,Pijoan JI,et al.Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout[J].ArthritisRheum,2002,47(4):356-360.
  • 4Siu YP,Leung KT,Tong MK,et al.Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level[J].Am J Kidney Dis,2006,47(1):51-59.
  • 5Thanassoulis G,Brophy JM,Richard H,et al.Gout,allopurinol use,and heart failure outcomes[J].Arch Intern Med,2010,170(15):1358-1364.
  • 6Chao J,Terkeltaub R.A critical reappraisal of allopurinol dosing,safety,and efficacy for hyperuricemia in gout[J].Curr Rheumatol Rep,2009,11(2):135-140.
  • 7Stamp LK,O'Donnell JL,Zhang M,et al.Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chro-nic gout,including those with renal impairment[J].Arthritis Rheum,2011,63(2):412-421.
  • 8Takahashi S,Moriwaki Y,Yamamoto T,et al.Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartanon uric acid metabolism[J].Ann Rheum Dis,2003,62(6):572-575.
  • 9Gopal CS,David BK,Choi Y,et al.Arhalofenate,a potential novel treatment for hyperuricemia,with or without metabolic co-morbidities,in pa-tients with gout:meta-analysis of urate lowering in four phase 2 studies in type 2 diabetes[J].Arthritis Rheum,2011,63(Suppl 10):S1014.
  • 10Oh JS,Choi SW,Koo BS,et al.Efficacy of combined treatment with allopurinol and benzbromarone in gout patients with chronic renal impairment[J].Ann Rheum Dis,2011,63(Suppl 10):S401.

共引文献46

同被引文献58

  • 1吴国光,邓志辉,高素青,程良红,金士正,周丹,李桢,邹红岩,张旋,魏天莉,程曦,王大明.6965名汉族骨髓供者HLA多态性分析[J].中华血液学杂志,2004,25(8):473-477. 被引量:96
  • 2吴静.调脂药物的一支独秀——非诺贝特的独特作用及其临床应用[J].实用糖尿病杂志,2005,1(5):59-61. 被引量:18
  • 3焦根龙,李志忠,潘永勤.腰椎间盘突出合并右侧关节突关节痛风石1例报告[J].中国脊柱脊髓杂志,2007,17(12):942-943. 被引量:9
  • 4Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemiaand hyperuricemia: effects of two fibric acid derivatives(bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial [J]. Metabolism, 1988,37(3): 217-220.
  • 5Chohan S, Becker MA. Update on emerging urate-loweringtherapies [J]. Curr Opin Rheumatol, 2009,21(2): 143-149.
  • 6Suk KS, Kim KT, Lee SH, et al. Tophaceous gout of thelumbar spine mimicking phylogenic discitis [J]. Spine J,2007,7(1): 94-99.
  • 7Hou LC,Hsu AR, Veeravagu A, et al. Spinal gout in a renaltransplant patient: a case report and literature review [J]. SurgNeurol, 2007,67(1): 65-73.
  • 8朱迅.手术治疗痛风性关节炎痛风石13例疗效观察[J].中外健康文摘,2012, 9(16): 112-113.
  • 9Schumacher HR, Evans RR, Saag KG, et al. Rilonacept(interleukin-1 trap) for prevention of gout flares duringinitiation of uric acid-lowering therapy: results from aphase III randomized, double-blind, placebo-controlled,confirmatory efficacy study [J]. Arthritis Care Res, 2012,64(10): 1462-1470.
  • 10So A, Meulemeester MD, Pikhlak A, et al. Canakinumab forthe treatment of acute flares in difficult-to-treat gouty arthritis:resuits of a multicenter, phase II’ dose-ranging study [J].Arthritis Rheum, 2010, 62(10): 3064-3076.

引证文献8

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部